Triciribine (API2; NSC 154020; VQD002)
This product is for research use only, not for human use. We do not sell to patients.
For small sizes, please check our retail website as below: www.invivochem.com
| Size | Price | Stock |
|---|---|---|
| 250mg | $925 | Check With Us |
| 500mg | $1380 | Check With Us |
| 1g | $2070 | Check With Us |
: Cat #: V0162 CAS #: 35943-35-2 Purity ≥ 98%
Description: Triciribine (also known as API-2; NSC-154020; VQD-002), a cell-permeable tricyclic nucleoside molecule, is a potent DNA synthesis inhibitor with potential anticancer activity.
Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 320.30 |
|---|---|
| Molecular Formula | C13H16N6O4 |
| CAS No. | 35943-35-2 |
| Storage | -20℃ for 3 years in powder formr |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO:64 mg/mL (199.8 mM)r |
| Water: <1 mg/mLr | |
| Ethanol: 5 mg/mL (14.8 mM) | |
| Solubility In Vivo | 1% DMSO+30% polyethylene glycol+1% Tween 80: 30mg/m |
| SMILES Code | O[C@H]1[C@H](N2C=C3C(N)=NN(C)C4=NC=NC2=C34)O[C@H](CO)[C@H]1O |
| Synonyms | NSC-154020; NSC 154020; NSC154020; Triciribine; VQD-002; VQD 002; VQD002; |
| Protocol | In Vitro | The nucleoside analog Triciribine (TCN) is a purine analog which is initially shown to inhibit DNA synthesis. Triciribine selectively inhibits the phosphorylation and activation of all three Akt isoforms. At a concentration of 10 μM Triciribine Akt phosphorylation is inhibited at both Thr308 and Ser473. Triciribine effectively inhibits the phosphorylation and consequently the catalytic activity of Akt in PC-3 cells. |
|---|---|---|
| In Vivo | Triciribine (TCBN) treatment, administered for 7 days after 14 days of hypoxia until 21 days of hypoxia is reached, reversed the vascular thickening as shown by immunohistochemistry and Western analyses. On the other hand, Rapamycin treatment did not prevent hypoxia-induced pulmonary alveolar haemorrhage and congestion. Triciribine partially inhibits progressive pruning of the vasculature. |
These protocols are for reference only. InvivoChem does not
independently validate these methods.
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 3.1221 mL | 15.6104 mL | 31.2207 mL | 62.4415 mL |
| 5mM | 0.6244 mL | 3.1221 mL | 6.2441 mL | 12.4883 mL |
| 10mM | 0.3122 mL | 1.5610 mL | 3.1221 mL | 6.2441 mL |
| 20mM | 0.1561 mL | 0.7805 mL | 1.5610 mL | 3.1221 mL |
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start)
×
Volume(start)
=
Concentration(final)
×
Volume(final)
This equation is commonly abbreviated as: C1 V1 = C2 V2
Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg
Average weight of animals g
Dosing volume per animal µL
Number of animals
Step Two: Enter the in vivo formulation
%DMSO
+
%
+
%Tween 80
+
%ddH2O
Calculation Results:
Working concentration:
mg/ml;
Method for preparing DMSO master liquid:
mg
drug pre-dissolved in
µL
DMSO(Master liquid concentration
mg/mL)
,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:
Take
µL
DMSO master liquid, next add
µL
PEG300, mix and clarify, next add
µL
Tween 80,mix and clarify, next add
µL
ddH2O,mix and clarify.
Note:
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.